Genfit S.A. (NASDAQ:GNFT) Short Interest Up 6.0% in January

Genfit S.A. (NASDAQ:GNFT) was the target of a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 63,400 shares, a growth of 6.0% from the December 31st total of 59,800 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average daily volume of 10,100 shares, the days-to-cover ratio is presently 6.3 days.

Genfit Stock Down 2.9 %

Shares of GNFT opened at $3.74 on Wednesday. The company has a quick ratio of 3.74, a current ratio of 3.74 and a debt-to-equity ratio of 0.61. Genfit has a 1 year low of $3.35 and a 1 year high of $6.42. The business’s 50 day simple moving average is $3.78 and its 200-day simple moving average is $4.44.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $13.00 price target on shares of Genfit in a report on Friday, October 11th.

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.